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de Torres JP, Casanova C, Marin JM et al.
Exploring the impact of screening with
low-dose CT on lung cancer mortality in mild
to moderate COPD patients: A pilot study.
Respir Med 2013; 107: 702e707We congratulate de Torres and colleagues on their recently
published pilot study reporting a significant survival
advantage in patients with mild to moderate COPD diag-
nosed with lung cancer using computed tomographic (CT)
screening [1]. We agree that while further studies are
needed, their results raise three important issues about
targeted CT screening.
First, the lung cancer detection rate (LCDR, number of
lung cancers detected per person screened) in their mild to
moderate COPD patients was 2.31 per annum, about 3.8 fold
that reported in theNational Lung Screening Trial (NLST, 0.61
per annum) where smokers were selected only on age and
pack year history. This result confirms our findings from a re-
analysis of the Pittsburgh Lung Screening Study (PLuSS)
where, after stratifying those in the screening study by
spirometry-defined COPD (GOLD 1-4), we showed a 4.5 fold
increase in LCDRcompared to thosewith normal lung (1.5% vs
0.33 per annum) [2]. As the cost of spirometry is much lower
than that of a CT scan, targeting pre-selection to those with
mild to moderate COPD lowers the number needed to screen
to find one lung cancer case (NNS) from 1 in 164 people
screened per annum to one in 43 people with mild-moderate
COPD, making CT screening substantially much more cost
effective in patients with COPD. However, it is noted that
limiting CT screening to just those with mild to moderate
COPD lowers eligibility sensitivity to only 50% of all those
developing lung cancer [3,4], comparable to the 47% we
estimated using the NLSTeligibility criteria, where strict age
and smoking criteria were used to select screening partici-
pants [5].
The second interesting finding is the apparent
“absence” of over-diagnosis when mild to moderate COPD
patients undergo CT screening given equal (albeit veryDOI of original article: http://dx.doi.org/10.1016/
j.rmed.2013.01.013.
http://dx.doi.org/10.1016/j.rmed.2013.06.022
0954-6111/ª 2014 Elsevier Ltd. All rights reserved.modest) numbers of cancers detected in each arm [1]. In
contrast, CT screening studies using only age and smoking
history eligibility criteria have consistently reported an
“excess” of between 35 and 65% of lung cancer cases in the
CT arm above that of controls (unscreened or CXR-
screened) [6e8]. When the histology of the lung cancer
cases are compared, there is a consistent excess of bron-
chioloalveolar cancers and adenocarcinomas in the CT arm
compared to control arms (i.e. “Histology shift”, see
Table 1) [6e8]. Importantly, these histological subtypes of
lung cancer have been strongly associated with longer
doubling times [4,9] and better lung function [10]. A
similar finding was recently reported in the COSMOS CT
screening study [10]. If mild to moderate COPD is associ-
ated with more aggressive forms of lung cancer, this might
explain the significant stage shift (80% vs 20% stages I-II)
and mortality reduction (0.3% vs 3.6% at 31 months
respectively) reported by the de Torres study [1]. Such a
finding could be explained by the molecular data showing
COPD is characterised by an excess of matrix metal-
loproteinases (lung remodelling), growth factors (repair)
and airway inflammation that combine to generate a
“remodelling/repair micro-climate” strongly favouring
cancer development (or progression) in the bronchial
epithelium [11,12].
Lastly, if targeted CT screening of high risk smokers
benefits those with mild to moderate COPD, then failing to
perform routine spirometry in asymptomatic smokers may
no longer be tenable. We have recently raised concerns
about guidelines on the diagnosis and management of COPD
that discourage the use of screening spirometry in asymp-
tomatic smokers (many with undiagnosed mild to moderate
COPD) [13,14]., Indeed if anything like the 12 fold decrease
in mortality described by de Torres and colleagues is
confirmed in a larger study, then discouraging the routine
use of spirometry to diagnose these early forms of COPD in
asymptomatic current or former smokers may be
completely unjustified [14].
We conclude that although a larger study is needed to
confirm the mortality reduction reported by de Torres and
colleagues, there is growing evidence that a “COPD-
centric”, but not exclusive, approach to CT screening for
lung cancer may offer many advantages over current rec-
ommendations limited to age and pack year eligibility
criteria.
Table 1 Histology of “excess cancers” from the National Lung Screening Trial (NLST) [6] and Danish Lung Screening Trial
(DLST) [7] e Does a “Histology shift” partly underlie over-diagnosis?.
Histology NLST DLST
CT (%) CXR (%) Diff (CT-CXR) % Diff CT (%) Usual (%) Diff (CT-no CT) % Diff
Bronchioloalveolar 110 (10.5%) 35 (3.8%) þ75 þ68% 6 (8.7%) 0 (0%) þ6 þ100%
Adenocarcinoma 380 (36%) 328 (25%) þ52 þ14% 42 (61%) 10 (42%) þ32 þ76%
Squamous Cell 243 (23%) 206 (22%) þ37 þ15% 8 (12%) 3 (13%) þ5 þ63%
Non-small Cell 172 (16%) 201 (22%) 29 14% 10 (14%) 4 (17%) þ6 þ60%
Small Cell 137 (13%) 159 (17%) 22 14% 3 (4%) 7 (29%) 4 57%
Other 16 (1.5%) 12 (1.3%) þ4 þ25% 0 (0%) 0 (0%) 0 0
Total (full study) 1048 931 þ119 þ11% 69 24 þ45 þ65%
Total (1st 3 yrs)a 720 470 þ250 þ35% e e e e
a Excess cancers in NLST after 3 yearly screening rounds (specific histologies not reported).
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